Pharmacokinetic Evaluation of Testosterone Gel (1%)

Completed · Phase 1

Conditions studied: Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)

In brief

Measure and evaluate the level of testosterone in blood, and determine the safety and tolerability following daily applications of testosterone gel. Subjects who complete this trial may participate in the extension part (UMD-01-080E).

Key facts

Study ID

NCT00193700

Run by

Solvay Pharmaceuticals

Starts

2002-08-01

Last updated by the study team

2006-12-25

Who can join

Age: 13 and older, up to 17. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of primary or secondary hypogonadism or constitutional delay in growth and puberty (CDGP)

You may not qualify if…

• Clinically significant uncontrolled medical condition or psychiatric disorder

Where it is running

• Site 208 — Birmingham, Alabama, United States
• Site 203 — Torrance, California, United States
• Site 204 — Jacksonville, Florida, United States
• Site 201 — Kansas City, Missouri, United States
• Site 206 — Morristown, New Jersey, United States
• Site 207 — Brooklyn, New York, United States
• Site 209 — Cincinnati, Ohio, United States
• Site 202 — Philadelphia, Pennsylvania, United States
• Site 205 — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.